Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Senti Biosciences Inc (SNTI)

Senti Biosciences Inc (SNTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,728
  • Shares Outstanding, K 4,589
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -71,060 K
  • EBIT $ -54 M
  • EBITDA $ -49 M
  • 60-Month Beta 2.74
  • Price/Sales 3.80
  • Price/Cash Flow N/A
  • Price/Book 0.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -4.20
  • Growth Rate Est. (year over year) +23,885.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +1.93%
on 11/19/24
2.47 -14.17%
on 11/15/24
-0.14 (-6.19%)
since 10/21/24
3-Month
2.00 +6.00%
on 10/14/24
3.29 -35.56%
on 09/20/24
-0.48 (-18.46%)
since 08/21/24
52-Week
1.52 +39.46%
on 08/07/24
7.43 -71.47%
on 01/02/24
-1.55 (-42.30%)
since 11/21/23

Most Recent Stories

More News
Senti Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Clinical Updates

Senti Bio reports Q3 2024 financial results, highlighting clinical progress for SENTI-202 and grant funding from CIRM.Quiver AI SummarySenti Biosciences, Inc. announced its third-quarter 2024 financial...

SNTI : 2.12 (unch)
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

SNTI : 2.12 (unch)
Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection...

BBAI : 2.19 (+4.78%)
SNTI : 2.12 (unch)
TNGX : 3.63 (-11.03%)
BOXD : 0.1898 (-15.27%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dynamics Special Purpose Corp., which merged with Senti Bioscience, Inc. ("Senti"...

SNTI : 2.12 (unch)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
SNTI : 2.12 (unch)
INBX : 13.98 (-0.43%)
IMVT : 26.54 (+1.41%)
AUTL : 2.84 (+1.43%)
BMY : 58.23 (+0.60%)
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

BMY : 58.23 (+0.60%)
ONC.TO : 1.37 (-2.14%)
ONCY : 0.9800 (-1.85%)
SNTI : 2.12 (unch)
INBX : 13.98 (-0.43%)
IMVT : 26.54 (+1.41%)
AUTL : 2.84 (+1.43%)
Chardan Announces Launch of ChEF (Chardan Equity Facility)

/PRNewswire/ -- Chardan, a global investment bank, has announced the launch of its Chardan Equity Facility (ChEF) product, an innovative financing solution...

SNTI : 2.12 (unch)
CNTQ : 14.00 (-8.14%)

Business Summary

Senti Biosciences Inc. is a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. Senti Biosciences Inc., formerly known as Dynamics Special Purpose Corp., is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 2.34
2nd Resistance Point 2.29
1st Resistance Point 2.20
Last Price 2.12
1st Support Level 2.07
2nd Support Level 2.02
3rd Support Level 1.93

See More

52-Week High 7.43
Fibonacci 61.8% 5.17
Fibonacci 50% 4.48
Fibonacci 38.2% 3.78
Last Price 2.12
52-Week Low 1.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar